LD-2 disclosure · 4th Quarter - Report
SHATTERPROOF
Client
- Name
- SHATTERPROOF
- Description
- Nonprofit organization focused on opioid policy issues.
- Location
- New York · United States of America
Registrant
- Description
- Law firm
- Location
- WASHINGTON, District of Columbia, United States of America
Lobbying activities
1 issueHealth Issues
Implementation of funding provided for in Consolidated Appropriations Act, 2021 (P.L. 116-260) to address substance use disorder; Mainstreaming Addiction Treatment Act (H.R. 1384/S. 445); Medication Access and Training Expansion Act (H.R. 2067/S. 2235); Medicaid Reentry Act of 2021 (H.R. 955/S. 285); Collaborate in an Orderly and Cohesive Manner Act (H.R.5218); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Synthetic Opioid Danger Awareness Act (H.R. 2364); FENTANYL Results Act (H.R. 2538/S. 1160); issues related to fentanyl; Consolidated Appropriations Act, 2023 (P.L. 117-328).
LobbyistsJULIE NOLAN · LOUIS AGNELLO · KATHLEEN MALLOY
Covered position (KATHLEEN MALLOY): Intern for Senator Tammy Baldwin, September-December 2020
TargetedSENATE · HOUSE OF REPRESENTATIVES · Health & Human Services, Dept of (HHS)